Benjamin Machinas Beneski insider trades: Allogene Therapeutics (ALLO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Benjamin reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | ALLO | ↓ Sell | 2,867 | $2.50 | $7K | Direct | Apr 2, 2026 (2d) |
| Mar 16, 2026 | ALLO | ↓ Sell | 4,835 | $2.47 | $12K | Direct | Mar 18, 2026 (2d) |
| Mar 2, 2026 | ALLO | ↓ Sell | 7,132 | $2.60 | $19K | Direct | Mar 4, 2026 (2d) |
| Feb 2, 2026 | ALLO | ↓ Sell | 7,549 | $1.73 | $13K | Direct | Feb 4, 2026 (2d) |
| Nov 17, 2025 | ALLO | ↓ Sell | 786 | $1.22 | $959 | Direct | Nov 19, 2025 (2d) |
| Mar 14, 2025 | ALLO | ↓ Sell | 5,488 | $1.98 | $11K | Direct | Mar 18, 2025 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ALLO insiders
Open-market trades in the last 12 months
About Benjamin Machinas Beneski's insider trades
Benjamin Machinas Beneski is SVP, Chief Technical Officer at Allogene Therapeutics (ALLO). Since Mar 14, 2025, Benjamin has reported no open-market purchases and 6 sales worth $63K on SEC Form 4. In the last 12 months: 5 sales ($52K).
Their filings also include grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ALLO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.